Latest news with #QueensUniversity
Medscape
a day ago
- Health
- Medscape
Skills Lab: Rethinking Surrogate Endpoints Approval
This transcript has been edited for clarity. Hello, everyone. This is Dr Bishal Gyawali, from Queens University, Kingston, Canada. Thank you for joining us in our Skills Lab video series. In the last lecture we discussed how progression-free survival (PFS) response rate and the surrogate endpoints are defined. We talked about the particularities with response rate and PFS, and in the adjuvant setting, with disease-free survival. Today we'll talk about surrogate endpoints and their role in regulatory approval. One question that people commonly ask is: What strength of surrogacy is required for drug approval? Are different strengths of surrogacy required for accelerated approval (or 'conditional' approval) vs regular approval (or 'full' approval)? We would expect that regular approval requires a higher bar of evidence as compared to accelerated approval. Unfortunately, there are no such published criteria, but based on the data we have seen, I think there are probably no unpublished criteria either. If we compare the response rates of drugs that have received accelerated approval vs regular approval, then we don't see much of a difference. Also, in one of these studies from 2002 to 2021, we saw that 30% of approvals were based on response rates from single-arm trials that received regular approval rather than next approval. You would believe that a response rate–based approval would usually be acceleratedor conditional approval so that the drug confirms clinical benefit in the future, but we found that in 30% of these cases, they received upfront, regular, full approval rather than accelerated approval. I call this upfront, premature, regular approval. If you look at the trends of the FDA approval, you'll notice in recent years that the number of approvals based onsurrogate endpoints is increasing, while simultaneously, the number of accelerated approvals is decreasing. At first, it does not make sense because accelerated approvals are supposed to be surrogate-based approvals. What this means is that nowadays we are approving more and more drugs on the basis of surrogate endpoints by giving them full or regular approval rather than accelerated approval, which I think is very concerning from a societal point of view. If we are giving upfront, regular approval, then we can never be sure that they confirm clinical benefit because they don't have a mandate to do such a confirmatory trial. Also, even if these drugs were to fail in subsequent trials, we can't withdraw them. Only accelerated approvals get withdrawn. I'll give you one example:the BOLERO-2 trial of everolimus in breast cancer. As you can see, the first graph is PFS, and there was a 6-month improvement in PFS, with a hazard ratio of 0.36, which led to the drug's approval. It was not accelerated approval; it was full approval. In just 2 years, the overall survival results were published. As you can see in the second graph, the overall survival was negative. Overall survival did not improve, but because it was a full approval, the drug was not withdrawn. I call this premature approval, and we should be asking why we are granting full approval based on surrogate data. One more example: Margetuximab in breast cancer was approved on the basis of PFS improvement. You can see how much PFS improvement there was. It was 5.8 vs 4.9 months, so it was just 0.9 months, or less than 1 month, of PFS improvement. This drug was given full approval, not accelerated approval like it was supposed to. You can look at the date. This drug was approved in December 2020, and just 9 months later, in September 2021, we received overall survival results from this trial. The drug failed to improve overall survival. If we had not given regular approval, then we would have withdrawn this drug, but because it was given premature full approval, the drug was not withdrawn. It took only 9 months to get overall survival data, so why did we not give accelerated approval? That is something we should be asking. We recently published a paper in JCO about why PFS should not be used as a primary endpoint for registration of anticancer drugs. We list several reasons why PFS fails to capture clinical benefit in these trials. I think we should at least agree that, if we're approving drugs based on surrogate endpoints, it should be accelerated or conditional approval and not full approval. The other common question is: If PFS did not lead to overall survival improvement, did it not improve quality of life? We tried to answer that question. First, of course, there is no reason for PFS to correlate with overall survival. As we discussed in the last lecture, nothing magical happens at 20% and not all progression events are the same. Some progression events are more symptomatic than others, therefore the quality-of-life effectis not always predictable. Quality-of-life impact is not only a function of how big the tumor is but also a function of drug toxicities. In recent years, we have seen that PFS has become the default primary endpoint. In the past decade or so, the frequency of trials using PFS at the primary endpoint has increased substantially and now exceeds the percentage of trials with overall survival as the primary endpoint. The strange thing about PFS is that we talk about correlation of PFS with overall survival and how we need to do correlation analysis to confirm that this is a valid surrogate as we saw with the case of bevacizumab in breast cancer, even after eight clinical trials were conducted, was PFS a good surrogate for overall survival in this setting? The answer was that we do not know. Maybe, maybe not. What I'm trying to say here is that, even after eight clinical trials of the same drug in the same setting, we are still unable to conclude definitively whether PFS is a goodsurrogate for overall survival. This means that it is far more expedient to just measure overall survival than to continue to do multiple trials and continue to guess whether PFS is a good surrogate for overall survival. Thank you very much. I'll see you in the next lecture, in which we will talk about physicians' and patients' understanding related to surrogate endpoints.
The Independent
a day ago
- Business
- The Independent
Belfast tech company invests £1.8m in cybersecurity solution for factory floors
A Belfast-based tech company has announced a near £2 million investment in creating cybersecurity software for the manufacturing sector. The move by ANGOKA is aimed at combating the threat of cyber attacks on digitised factory production lines. The company's Cosmic (Cybersecurity for Operational Systems in Manufacturing and Industrial Control) initiative will see it partnering with Queen's University's Advanced Manufacturing Innovation Centre (AMIC). The link-up has received around £1 million in grant aid financial support from Invest NI. Economy Minister Caoimhe Archibald attended the announcement of the £1.8 million investment on Monday. 'This investment by ANGOKA will help increase productivity, create good jobs and boost innovation across two of our priority sectors – cybersecurity and advanced manufacturing,' she said. 'It is the result of collaboration between government, academia and the private sector. And it has been enabled by the city and growth deal which established the Advanced Manufacturing Innovation Centre. So, today's announcement is a great example of our economic strategy paying dividends.' ANGOKA chairman Steve Berry said: 'With cyber threats growing in both scale and sophistication, demand for solutions that protect online devices has surged across the globe. 'Cosmic is a reaction to the growing need for cybersecurity adoption in the advanced manufacturing sector due to the detrimental impact any breaches could have on the operational resilience of manufacturing facilities. 'Our new solution will allow us to expand our core offering and achieve ambitious growth targets. It will be designed for ease of deployment both on existing and new manufacturing equipment. This seamless deployment will be a key enabler for breaking into new markets across the globe.' Over the next two years, AMIC will support the development of the software through product testing, identification of target customers for commercial deployments and acting as a point of contact with industry groups.
Irish Daily Mirror
3 days ago
- Sport
- Irish Daily Mirror
Olympic champion wins medal with new partner at European Rowing Championship
Fintan McCarthy and Konan Pazzaia have won bronze for Ireland in the men's double sculls at the European Rowing Championships in Bulgaria. It's a first medal at heavyweight for Skibereen legend McCarthy, while for Queens University star Pazzaia, it's a first major medal. McCarthy has famously won gold medals for Ireland at Olympic Games alongside longtime rowing partner Paul O'Donovan, but with O'Donovan unavailable, Pazzaia stepped in and helped get the job done. Miroslaw Zietarski and Mateusz Biskup of Poland took home gold in Plovdiv, while Ireland's duo had to settle for third place in a time of 6.05.48 as they took home the bronze medal. For McCarthy, it is a first medal in the heavyweight class after years dominating the lightweight division with O'Donovan. The pair won gold in the lightweight double sculls at the 2024 and 2021 Olympic Games, and the duo also have three World and two European golds at lightweight.
BBC News
16-05-2025
- Science
- BBC News
Belfast: Connswater shark sighting was 'quite a surprise'
A man has said he "couldn't believe" what he was seeing as he went for a bike ride in Victoria Park in east Tuesday evening, Thomas Davidson spotted a 4ft-long starry smooth-hound shark swimming in the Connswater River where the waterway meets Belfast species of shark has been seen in other urban areas such as the River Thames and the River Mersey Patrick Collins, a marine biologist at Queen's University, said while "it's not something you see everyday, it's not something super unusual either". "In the past I would occasionally have seen several 2-3lb mullet follow the tide in, but on this occasion I saw a much larger shape in the water adjacent to Airport Road," Mr Davidson told BBC News said this shape was "too big to be a mullet", so he stopped to take a closer look."A dorsal fin slowly broke the surface revealing that familiar profile that looked like a shark," he said."I quickly took out my phone and started to video this slow-moving fish as it meandered left and right up and downstream, getting mobbed by a few gulls."I couldn't believe what I was watching."The shark continued swimming in this section of river for about 30 minutes before moving upstream into a shadow area and Mr Davidson lost sight of it. "I felt very lucky to witness such a lengthy sighting and was left curious as to how far upstream it might go," he Connswater River rises in the Castlereagh hills and runs northwards through east Belfast, getting wider until it reaches the sea at Belfast river route includes the Connswater Greenway walking route and flows past CS Lewis Square and Connswater Shopping Davidson said he will "continue to look out for it and others in the future". 'Probably having its lunch' This type of shark mainly eat crabs and small crustaceans, marine biologist Dr Patrick Collins section of the river in Victoria Park probably contained crabs, and so this shark spotted by Mr Davidson was "probably just having its lunch", he said it is "not very common to find smooth-hounds in cities, but they have been recorded in the last few years". "It's a little bit unusual if you're walking your dog to find one that close to the city, and that easy to see, but they're not a rare animal," Dr Collins continued."They're found fairly commonly across the UK and Ireland. It's not an unusual occurrence to have them close to an urban centre because there's sea water there. "It's a bit like seeing a deer in farmland."He added that this type of shark poses no risk to the public."Because of movies like Jaws and some other strange public perceptions coming from that, there's this idea that all sharks are dangerous animals - they're a type of fish."These animals pose absolutely no threat to us whatsoever."
Medscape
07-05-2025
- Health
- Medscape
Skills Lab: Classifying and Defining Surrogate Endpoints
This transcript has been edited for clarity. Hello, everyone. This is Dr Bishal Gyawali, from Queens University, Kingston, Canada, continuing with our Skills Lab series on how to interpret the clinical trial publication well. In the past few videos, we have discussed the methods section and we touched briefly on surrogate endpoints. This is a pretty big topic, so we will continue discussing surrogate endpoints is much confusion about surrogate endpoints. There are several questions that people ask about surrogate endpoints. In these videos, we're trying to answer those, but it may not be comprehensive. If you want to get a comprehensive understanding of almost all the questions regarding surrogate endpoints in oncology, I highly recommend you read this publication, which we have recently published and is open access. Continuing with surrogate endpoints, we discussed in the last presentation about how to differentiate between prognostic and predictive surrogate endpoints. Today, let's talk about how we classify and define them. We classify them in different ways, and one of those ways is surrogate endpoints in the setting of early cancer drug trials, as in neoadjuvant and adjuvant setting trials, and in advanced-setting trials. Within the advanced setting, we have different types of surrogate endpoints, such as response rate, clinical response, partial response, and overall response rate, as well as progression-free survival. These are usually defined on the basis of criteria known as RECIST. RECIST stands for Response Evaluation Criteria in Solid Tumors, and that's classically what almost every clinical trial uses to define the surrogate endpoints in the advanced setting. First, let's talk about the goal of the RECIST criteria. Why was this developed in the first place? It was not developed to make therapeutic decisions or intended for drug approvals. The whole idea around RECIST was to help clinical trials define success or lack of success early on, without the need to wait for overall goal was to make those decisions about whether these should be tested in a phase 3, from a phase 2, and so on. You can read the RECIST publication in detail, but briefly, to classify under RECIST, you need a target lesion. There are conditions on what can classify as a target lesion and what cannot. Progression of disease, or PD, is classically defined as at least 20% increase in the sum of the maximum tumor diameters, with an absolute increase of at least 5 mm, or a development of a new lesion that was not there before, or death of the patient. Any of these will classify as disease progression, so we classically keep talking about progressive disease as a 20% increase in the size of the tumor. Complete response, as the name indicates, is complete disappearance of all lesions. Partial response is shrinkage in the sum of the maximum tumor diameters by at least 30%. Anything in between, meaning the tumor size has decreased less than 30%, or the tumor size has increased less than 20%, is called a stable disease. Anything in between disease progression and partial response is stable disease. Overall response rate, sometimes called objective response rate,isthe complete response rate plus the partial response rate, so the percentage of patients who had any response is the overall response rate. We also measure the duration of response, which is the duration after achieving response until the tumor starts to grow again. There are also some other, what I call make-believe, meaningless endpoints. For example, people talk about the clinical benefit rate, which is theoverall response rate plus the stable disease rate. The idea is that if the disease does not progress, then that's a clinical benefit. These do not correlate with any meaningful endpoint. People should not focus on the clinical benefit rate. Why we're defining this is to see why t hese surrogate endpoints do not necessarily correlate with overall survival or quality of life: (a) because these were not intended to be used as such; and (b) the way we define them is quite arbitrary. As you can see, there is nothing magical that happens at 20% progression or 30% shrinkage of the tumor. You can imagine that if a person has a disease progression of 18% vs 22%, that's not going to cause any meaningful difference. A disease might grow by only 10%, but if it's at a sensitive location, such as intracranial, then it could lead to some symptoms. Not all disease progression events will be the same; therefore, they do not correlate with clinical endpoints. Now let's talk about the early cancer trial setting. In the neoadjuvant/adjuvant setting, we have endpoints such as disease-free survival, invasive disease-free survival, event-free survival, metastasis-free survival, relapse-free survival, andpathologic complete response. Pathologic complete response deserves a special mention because it's used more as a prognostic marker. It's not reliable as a predictive marker, but it's reliable as a prognostic marker. That means, irrespective of how you achieve pathologic complete response, you'll have a good prognosis. That does not necessarily mean that a drug that improves pathologic complete response will improve survival. Event-free survival is basically disease-free survival, but in the neoadjuvant setting. Of course, it's not feasible to go through the definition of each and every endpoint here, so again, if you want to have a more comprehensive understanding, I refer you back to that publication where all these endpoints are defined. Another way of defining endpoints is that there can be response-based endpoints, such as the objective response, complete response, partial response, and pathologic complete response that we talked about, vs is important because they are measured and analyzed in a different statistical way. Time-to-event endpoints are any endpoints that are measured in terms of the time it takes for the event to happen. This includes disease-free survival, progression-free survival, and metastasis-free survival. All of these are time-to-event endpoints. Let's spend some time talking about response rate because it's getting more and more frequently used in clinical trials and also as a basis for approval, but it's a very weak surrogate. The correlation with overall survival is even weaker than progression-free survival. The other interesting thing about response rate is that there is no way to define success. If we are measuring response rate in a phase 2 or a single-arm trial, is a 30%response rate enough? Is a 50% response rate enough? Is a 20% response rate enough? In how many patients? In 50 patients? In 40 patients? There is no way to define success here. As I mentioned, this was not meant for approval or clinical use. This was meant for transitioning from phase 2 to phase 3. In fact, we did a comprehensive study on the response rate of placebo in randomized controlled trials of cancer drugs. You'd expect that placebo would have a 0% response rate, but we were surprised to find that even placebo had a 1% response rate. Complete response rate was, of course, zero with placebo. When you put that in context with what we're approving nowadays, this is 1% response rate overall. There were some typical examples. For example, I'm showing this trial in renal cell carcinoma where interferon was compared with placebo. In this particular case, placebo had a higher response than the drug. The response from the drug was 4.4% and placebo had a 6.6% response rate. In another example from desmoid tumors, placebo had an overall response rate of 20%. If you compare that with some of the drugs that we have approved on the basis of response rate, like a 12% response rate in the CheckMate 032 trial, a 15% response rate in the EZH-20221 trial, and a 70% response rate in KEYNOTE-224. These are not good enough response rates, but we're approving drugs on the basis of these very small response rates. We need to be very careful. I think that, even if we were to rely on the response rate, it has to be in the context of a randomized trial where we're comparing the response rate of the drug against the response rate of the comparator arm. Just relying on the response rate in a single-arm trial is very likely to give us false positives. Let's also talk about progression-free survival. We talked about progression-free survival in the last video, but I'd also like to mentionthat there are some specific occasions where progression-free survival absolutely cannot be relied on, such as in later-line therapy trials or in situations where the prognosis is so bad that survival events happen within a year. For example, if we're talking about second- or third-line cholangiocarcinoma, in pancreatic cancer trials, patients have a median survival of 6-8 months — and not even 6 monthsif we're talking about second or third line. In that situation, there is no sense to use progression-free survival because you can measure survival so quickly, and there is no point in having a drug that does not improve survival. When the prognosis is very short, especially for later-line therapy trials, progression-free survival cannot be used. For combination therapies, when we are combining drug A plus B vs drug A alone, of course if we combine two drugs, it will extend progression compared with one drug alone. The point to ask is whether combining up front is better than giving the same drug sequentially. Only overall survival can answer that. For maintenance therapies, these are situations where we continue on a treatment for a long time, where the standard of care actually is to do no treatment. If you're giving an active drug instead of not giving a drug, of course you'll extend progression. Does that lead to improved survival outcomes and should we subject all of our patients for that extended duration of treatment? In these situations, progression-free survival cannot be used. Let's spend some time on the adjuvant setting as well. In the adjuvant setting, I find it even trickier to rely on a surrogate endpoint, such as disease-free survival, as opposed to overall survival. In the adjuvant setting, by definition, we're treating all the patients, some of whom may not need treatment and some of whom may not benefit from treatment, but 100% of the patients will get toxicities. In this particular example, in this Kaplan-Meier graph, at the 2-year landmark, 22% of the patients have relapsed or died even after getting the drug. There are 67% of patients who did not relapse even if they only received placebo. We are benefitting only that small margin of patients, that 11% of patients who benefited from getting the drug. Again, in this situation, we should also ask whether the patients who received placebo in this trial actually received the drug when they relapsed and how it affected overall survival. We had this publication where we advocate to use the approach of three E's — evidence, ethics, and economics — to decide whether or not treating all the patients upfront on the basis of disease-free survival or surrogate endpoints is better than treating only the patients who relapse at the time of their relapse. That ends our video for today. In the next video, we'll continue discussing some additional considerations about surrogate endpoints.
